IMPORTANCE Large studies investigating clinical presentation and treatment in primary conjunctival melanoma (CM) are rare. Clinicopathological characteristics of BRAF-mutated CM have not been studied thoroughly.
C onjunctival melanoma (CM) is an uncommon malignant neoplasm that makes up 5% of ocular melanomas and has an associated mortality of up to 30%. [1] [2] [3] Several clinical factors have been associated with this high mortality, including tumor size, extrabulbar location (ie, fornical or palpebral), or caruncular location and invasion of adjacent tissues. 2, [4] [5] [6] [7] The management of CM is controversial and has primarily evolved from physician experience and the findings of case series. 2, 6, 8 Previously, many patients having primary conjunctival malignant melanoma were treated with orbital exenteration. 9 Local excision and cryotherapy, adjuvant topical mitomycin C, and brachytherapy are widely used primary treatment modalities. 4, 6, 7, 10, 11 Incisional biopsies and excision without adjuvant therapy are discouraged because these methods appear to correlate with increased tumor recurrence rates, CM metastasis, and CM-related mortality. 2, 6, 8 Recurrent disease is common and has been reported to occur in approximately 50% of patients, and local recurrence has been associated with increased mortality. 1, 6, 7, 10, 11 In cutaneous melanoma, constitutive activation of the RasRaf-MEK-ERK (MAPK) signaling pathway via somatic activating mutations in BRAF (OMIM 164757) is present in 40% to 60% of cases. 12 BRAF mutations in cutaneous melanoma have been associated with a distinct clinical presentation and a poor clinical outcome. 13 As a consequence, targeted treatment with BRAF and MEK inhibitors has improved survival in patients with BRAF-mutated metastatic melanoma. 14 Investigations of genetic abnormalities in CM have revealed BRAF mutations in up to 50% of cases. [15] [16] [17] [18] [19] [20] [21] However, the associations of BRAF mutations in CM with clinical presentation and outcome are unclear. The objective of this study was to determine the associations of clinical presentation and treatment of CM with BRAF mutations, onset of local recurrence, metastasis, and mortality in a clinically well-defined population-based cohort of CM diagnosed in Denmark over a 52-year period.
Methods

Patient Data and Tumor Samples
In total, 139 patients were identified as being diagnosed as having CM from January 1, 1960, to December 31, 2012 , by searching the pathology reports at the Eye Pathology Institute, Copenhagen, Denmark (an institution providing nationwide service to Danish hospitals and ophthalmology practices) and the Danish Registry of Pathology. Conjunctival melanoma cases with origin in the conjunctiva or eyelid margin were included. Patients with primary cutaneous melanomas were excluded. Clinical patient records, pathology reports, and death certificates were collected and reviewed, and the Danish Registry of Pathology and the Danish Register of Causes of Death were searched to collect information on clinical presentation, treatment, local recurrence (recorded if recurrence was reported in the same eye at any site and with a histopathological diagnosis of CM), regional and distant metastasis, and cause of death. Tumor thickness (measured from the epithelial surface to the deepest tumor cell) and origin (primary acquired melanosis with atypia [PAM+], PAM+ and nevus, nevus, or de novo) were reviewed using the original hematoxylin-eosin stains. The TNM classification in the seventh edition of the Cancer Staging Manual by the American Joint Committee on Cancer was used. 22 Patient data and formalin-fixed, paraffinembedded (FFPE) tissue were available from 47 consecutive CM samples identified in more recent years (January 1, 1994, to December 31, 2012). All-cause mortality, melanomarelated mortality, development of distant metastasis, development of any (regional or distant) metastasis, and local recurrence were considered primary outcomes. This study adhered to the tenets of the Declaration of Helsinki, with institutional review board approval and health information privacy agency approval obtained from the Danish Data Protection Agency and the Local Scientific Ethics Committee. The Danish National Ethics Committee did not require informed consent because most patients were deceased at the time of study approval.
BRAF Mutation Analysis
DNA was extracted from the 47 FFPE tumor samples using a solution and tissue kit (QIAamp deparaffinization solution and DNA FFPE tissue kit; Qiagen) according to the manufacturer's instructions. Detection and quantification of BRAF mutations (c.1799T > A, p.V600E and c.1798_1799GT > AA, p.V600K) were performed by droplet digital polymerase chain reaction (ddPCR) analysis using an available system (QX200; Bio-Rad Laboratories) and hydrolysis probe-based assays (PrimePCR ddPCR mutation detection assays; Bio-Rad Laboratories). The PCR mixture contained 11 μL of ddPCR Supermix (Bio-Rad Laboratories) for probes, 1.1 μL of mutation primer or probe mix (FAM dye), 1.1 μL of wild-type primer or probe mix (HEX dye), and 5 μL of DNA (11.6-508.4 ng/μL) in a total volume of 22 μL. Twenty microliters of this mixture and 70 μL of droplet generation oil were transferred to different wells of a droplet generation cartridge. After emulsification of the samples using the droplet generator, samples were transferred to a 96-well PCR plate and amplified for 40 cycles at 94°C for 30 seconds and at 55°C for 60 seconds. Droplets were analyzed on the droplet reader, and a software program (QuantaSoft, version 1.4.0.99; Bio-Rad Laboratories) was used for analyzing DNA concentrations. Cutoff settings were determined using mutation-positive and mutation-negative control DNA samples.
At a Glance
• The objective of this study was to determine the associations of clinical presentation and treatment with prognosis and BRAF mutations in primary conjunctival melanomas. Data on primary treatment were obtained for 129 patients. Incisional or diagnostic biopsy was performed before other treatment in 27 patients. Most patients were treated with excision of the tumor combined with adjuvant therapy, which consisted of cryotherapy (n = 52), cryotherapy and topical chemotherapy (n = 3), brachytherapy with a ruthenium 106 plaque (n = 3), and irradiation with strontium 90 (n = 12). Thirtyseven patients were treated with excision without any further treatment, and enucleation or exenteration was the choice of treatment in 22 patients. Sentinel lymph node biopsy was performed in 3 patients, all initially seen with eyelid skin involvement. Among 129 cases, the histopathological origin was PAM+ in 62.0% (n = 80), nevus in 25.6% (n = 33), de novo in 10.9% (n = 14), and PAM+ and nevus in 1.6% (n = 2). All CMs invaded the substantia propria, and 57.6% (72 of 125) exceeded 1.5 mm in thickness. In total, 73.0% (27 of 37) of CMs involving the extrabulbar conjunctiva exceeded 1.5 mm in thickness. Local recurrence developed in 61 of 126 patients (46.2%), and regional metastasis was recorded in 16 of 132 patients (12.1%) and most commonly involved the preauricular lymph nodes, lymph nodes within the parotid and submandibular glands, and unspecified lymph nodes in the head and neck region. Distant metastasis developed in 30 of 132 patients (22.7%) and most commonly involved skin (cutaneous or subcutaneous) at several different sites (scalp, neck, shoulder, or leg), parotid or submandibular glands, brain, liver, lungs, or multiple sites. Thirteen of 132 patients (9.8%) developed subsequent or concurrent regional and distant metastasis. Fifty of 132 patients (37.9%) were alive at the end of the follow-up period, 33 of 132 (25.0%) died of melanoma-related causes, 45 of 132 (34.1%) died of other causes, and 4 of 132 (3.0%) died of an unknown cause.
Extrabulbar location of tumors (with involvement of the fornix, palpebral conjunctiva, or eyelid margin) was associated with increased melanoma-related and all-cause mortality hazard ratios (HRs) of 2.72 (95% CI, 1.12-6.59; P = .03) and 2.21 (95% CI, 1.25-3.90; P = .006), respectively. Invasion of adjacent tissue was associated with the development of distant metastasis or any metastasis (HR, 3.38; 95% CI, 1.21-9.45; P = .02 and HR, 3.04; 95% CI, 1.13-8.18; P = .03). Six CM cases involving the caruncle showed no significant associations with local recurrence, metastasis, or mortality. No significant associations of tumor origin with outcome were identified. However, increased risk of all-cause mortality in melanoma developed de novo (HR, 1.94; 95% CI, 0.98-3.84; P = .06) was identified. Compared with PAM+, melanoma from a nevus may have been associated with a lower risk of local recurrence (HR, 0.41; 95% CI, 0.16-1.07; P = .07) and any metastasis (HR, 0.51; 95% CI, 0.25-1.02; P = .06).
Patients undergoing incisional biopsy more frequently developed distant metastatic disease (HR, 2.46; 95% CI, 1.08-5.58; P = .03). Patients treated with excision without adjuvant treatment more frequently developed local recurrence (HR, 1.97; 95% CI, 0.11-3.48; P = .02) and distant metastasis (HR, 2.51; 95% CI, 1.07-5.91; P = .03) and had increased melanomarelated mortality (HR, 2.27; 95% CI, 0.97-5.33; P = .06) and all-cause mortality (HR, 1.80; 95% CI, 1.05-3.08; P = .03).
BRAF Mutations
BRAF mutation analysis was performed in a subset of 47 consecutive patients ( Table 2) . Analysis of tumor DNA using ddPCR led to identification of BRAF mutations in 19 of 47 patients (40.4%). Mutations were V600E type in 15 of 19 (78.9%) and V600K type in 4 of 19 (21.1%) ( Figure) . BRAF mutations were more common in younger patients (P = .005, Mann-Whitney test), were less common in the extrabulbar conjunctiva (P = .05, Fisher exact test), and rarely were initially seen with PAM (P = .001, χ 2 test).
The tumor most commonly had a mixed pigmented or nonpigmented appearance (P = .006, χ 2 test). BRAF-mutated CMs were more frequently classified as T1 tumors (P = .03,χ 2 test). Conjunctival melanomas with a histopathological origin in PAM+ were BRAF mutated in 36.1% (13 of 36), whereas CMs associated with a nevus were BRAF mutated in 66.7% (6 of 9). Distant metastasis occurred in 7 of 47 patients (14.9%) and more frequently developed in patients with BRAF-mutated CM (n = 6) as opposed to BRAF wild-type CM (n = 1). A KaplanMeier model showed decreased distant metastasis-free survival in BRAF-mutated CM (P = .02, log-rank test). The presence of BRAF mutations in primary CM showed no association with local recurrence, regional metastasis, or mortality ( Table 3) . Multivariable Cox proportional hazards regression showed no association with local recurrence, metastasis, or mortality (Table 1) .
Discussion
We present a retrospective investigation of clinical prognostic features, treatment, and BRAF mutations in patients with CM in Denmark. Our findings represent unique national data acquired for more than 50 years. The sex ratio of patients with CM was approximately 1:1, and the median age at diagnosis was 67.2 years, which is slightly older than is reported in other Nordic countries. 3, 7 Most CMs were located in the bulbar conjunctiva, similar to what has been reported previously. 3, 6, 7, 10, 11, 23, 24 Conjunctival melanomas involving the extrabulbar conjunctiva and manifesting with involvement of adjacent tissue structures were associated with a poor prognosis. The higher risk of metastasis and melanomarelated death for extrabulbar CM is in agreement with other studies. 6, 7, 10, 11, [23] [24] [25] [26] [27] However, increased mortality for CM cases involving the plica and caruncle could not be confirmed.
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Significant associations with outcome were not identified for tumor diameter, which could be because of the few measurements obtained. Increasing tumor thickness was not associ- ated with a poor outcome, which may be due to the adjustment for tumor location in multivariable analysis because 73.0% (27 of 37) of extrabulbar tumors exceeded 1.5 mm. All tumors invaded the substantia propria. However, depth of invasion was excluded in the present study because it is not included in the current TNM classification. 22 Caution against performing incisional biopsies has been stated in several studies. 2, 6, 23, 28 However, to our knowledge, the present study is the first to show an association of incisional biopsies with distant metastasis regardless of subsequent treatment. Therefore, the use of incisional biopsies is discouraged.
Despite the retrospective nature of our study, a poor prognosis in patients treated with excision alone was observed, which has also been reported in other case series. 6, 23 Tumor origin may influence the poor outcome observed in patients treated with excision alone because of the tendency for more frequent local recurrences and metastases in CM originating in PAM+ and the fact that treatment practices changed over the considerably long follow-up period. Therefore, our results also reflect the variation in practice over time in the performance of incisional biopsies and excision without adjuvant therapy. We had insufficient data to evaluate differences in surgical techniques (lamellar scleroconjunctival excision vs simple conjunctival excision) or prognostic information from sentinel lymph node biopsies. Recent results showed improvement in local recurrence rates when brachytherapy alone or in combination with local chemotherapy was performed. 4, 8, 29 This treatment is the preferred choice at our institution. Forty-seven CMs were analyzed for BRAF mutations in the present study, representing a large number of patients compared with previous studies. BRAF mutations were identified in 40.4% (19 of 47) of the tumors. The frequency of BRAF mutations in CM has varied between 0% and 50% in previous studies. [15] [16] [17] [18] [19] [20] [21] Small sample size, the use of different detection methods, and a lack of assessment of V600K-type mutations could explain these differences. The distribution of V600E and V600K-type mutations in the present study corresponded well with that reported in cutaneous melanoma, in which V600K may be present in up to 20% of BRAF-mutated tumors.
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Therefore, future studies should also include investigations of the V600K-type mutation. Patients having tumors with the BRAF mutation were younger at diagnosis compared with patients having wild-type CM, which has also been reported in cutaneous melanoma. 13 BRAF mutations occurred more frequently in the bulbar, corneolimbal, and caruncular conjunctiva and were more frequently classified as T1 tumors. An increase in the incidence of CM in recent years has been reported, particularly for cases developing in areas of the conjunctiva exposed to UV radiation. 3, 7, 31 It is likely that this increase is also linked to an increase in BRAF mutations because these mutations appear more frequently at these sites. However, this theory needs to be investigated in larger patient series. A high frequency of BRAF mutations in tumors without PAM and in tumors with a mixed pigmented or nonpigmented appearance was observed. The appearance of these tumors could be due to different tumor clones. The distribution of BRAF mutations within these clones remains to be investigated. A higher proportion of BRAF mutations in CM with origin in a nevus was observed, although statistical analysis of this finding does not rule out the possibility that this difference was due to chance. An association of BRAF mutations with nevi has been reported previously 17, 18 and corresponds well with the few BRAF-mutated tumors with clinically evident PAM in the present study. When associating BRAF mutation status with outcome, an association with the development of distant metastatic disease was identified in univariate analysis. However, a definitive association was no longer identified in multivariable Cox proportional hazards regression models, which could be owing to the small proportion of tumors tested or the possibility that confounding factors rather than the BRAF mutations accounted for the association noted in univariate analysis. Additional studies evaluating the association of BRAF mutations with this outcome would be needed to increase the confidence that BRAF mutations are truly associated with this outcome. Bulbar location in CM is usually associated with a fair prognosis, 6, 7, 10, 11, 27 which contrasts with our findings of more frequent distant metastases in BRAF-mutated bulbar CM. Previous studies [15] [16] [17] [18] [19] [20] [21] investigating BRAF mutations in CM have not shown significant associations with prognosis. In a study by Lake et al, 19 however, 50% of BRAF mutations were found in CM metastases. In addition, BRAFmutated cutaneous melanoma has been associated with increased risk of melanoma-related mortality and a high propensity to metastasize. 32, 33 Considering the similarities between cutaneous melanoma and CM, it seems reasonable to assume that the same associations would apply to CM. However, the results should be interpreted with caution because of the few distant metastases and the limitations of our statistical analyses.
Conclusions
A poor prognosis of extrabulbar CM and CM with local invasion was confirmed. A higher risk of distant metastasis was identified in patients with CM in whom incisional biopsy was performed. performed a retrospective review of primary conjunctival melanomas; the cohort represented a 50-year retrospective assessment of specimens identified in the Eye Pathology Institute at the University of Copenhagen. The authors performed an analysis looking for BRAF mutation in all specimens when available. The main outcome measures included local and regional recurrences as well as melanoma-related mortality. The volume of cases in this report is impressive with 139 patients reviewed and a subset of 47 tumors analyzed for BRAF mutation. The study confirmed previous findings with regard to location-extrabulbar conjunctival melanomas are associated with the worst prognosis. The study did not identify or correlate tumor thickness, which has been identified as an important risk factor for regional spread. Nor did the authors address in depth the significance of primary acquired melanosis as a risk factor for development of frank melanoma. The latter are 2 very important features that surgeons should consider in their treatment strategy and stratification of highrisk patients.
The authors identified BRAF mutations in nearly 40% of primary conjunctival melanomas and that these mutations were more frequent in younger patients. Metastasis was identified as more frequent in BRAF-mutated melanomas. Finally, the study demonstrates that patients undergoing incisional biopsy developed higher rates of metastasis and that excision without adjuvant treatment was associated with frequent local occurrences.
The report highlights a number of recommendations for the comprehensive ophthalmologist and the practicing ocular oncologist. For the comprehensive ophthalmologist, it emphasizes the importance of presurgical planning and strong consideration for excisional biopsy for suspicious conjunctival lesions. While many conjunctival melanomas are pigmented, amelanotic lesions can simulate other benign and malignant processes and the surgeon must carefully consider the risk and the benefits of an incisional vs an excisional biopsy. The findings of Larsen et al suggest that an incisional biopsy may be associated with higher rates of metastases and overall patient mortality. In my opinion, for these reasons an excisional biopsy should be the preferred approach for the vast majority of suspicious conjunctival lesions and any surface neoplasm where the differential diagnosis includes conjunctival melanoma. 2 For the practicing ocular oncologist, the report also confirms the benefits of adjuvant therapy in addition to excision to reduce rates of lower recurrence. Although the authors do not specifically identify a preferred adjuvant therapy, most surgeons agree that surgical excision combined with cryotherapy and topical chemotherapy are the most common modalities used for this neoplasm. 2 Of great interest are the large percentage of cases with BRAF mutations. Mutational analysis in the field of cutaneous melanoma has significantly impacted treatment strategies for patients with regional and distant recurrence. The majority of cutaneous melanomas harbor a BRAF mutation. 3 In contrast, most uveal melanomas harbor a GNAQ or GNA11 mutation.
At present, mutational analysis does not directly impact local treatment strategies for conjunctival melanoma; however, high-risk cases at risk for distant metastasis may benefit from such an assessment. Thick melanomas or those involving the extrabulbar location may be such candidates. In many tertiary cancer centers, sentinel lymph node biopsy is a modality that may detect clinically asymptomatic lymph node involvement. 4 Although this approach has not proven to alter survival, patients with a positive lymph node undergo a full neck dissection and are upstaged with regard to their cancer. It is these cases, where knowledge of BRAF mutational status may have direct implications and benefit to additional treatment options. In my opinion, any young patient with a BRAF-positive conjunctival melanoma should be monitored closely for recurrent and distant disease and counseled appropriately. While at present mutational analysis does not directly impact local treatment strategies, it is not unreasonable to foresee a day where mutational analysis may alter topical adjuvant therapies, such as treatment directed toward various pathways including the map kinase pathway. In summary, the main clinical pearl from this report is the reaffirmation that management of conjunctival melanocytic 
